Otonomy Snags Approval for Otiprio
The FDA has given the green light to Otonomy’s Otiprio for the treatment of pediatric patients with bilateral otitis media with effusion undergoing tympanostomy tube placement.
A single-dose antibacterial, Otiprio (ciprofloxacin otic suspension) is the first product approved for this indication, according to the company.
Otonomy spokeswoman Heidi Chokeir says the company has a preliminary net sales price target of $200 to $250. The company plans to launch the product in the first quarter of 2016.